Abstract: Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.

Abstract: Disclosed herein are methods of making pure chalcogenide (e.g., selenium, tellurium, or selenium/tellurium) nanoparticles by irradiating chalcogenide pellets by nano-second laser ablation using chitosan as a capping agent to form chitosan chalcogenide nanoparticles (CS-CgNPs). CS-CgNPs and methods of using such particles are also disclosed herein, such as antimicrobials and antimicrobial coatings effective against biofilms.

Abstract: The present invention relates to the reduction of oxidative stress, the improvement of the system, the provision of healthy cartilage, as well as the alleviation of pain in ruminants.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: The various aspects presented herein relate to the field of antimicrobial compositions and their use as antibacterial agents, or their use for the preparation of antimicrobially active perfuming compositions and consumer products.

Abstract: Bacteriophage covalently attached to a carrier particle with an average diameter of from 0.1 microns to 15 microns, are used in topical treatment of bacterial infection. Bacteriophage covalently attached to a carrier particle of average diameter 7 microns or less are used in systemic treatment of bacterial infection. A plurality of bacteriophages lytic against different bacterial strains gives wide antibacterial activity. A combination therapy comprises administration of antibiotic and bacteriophage covalently attached to a carrier particle.

Abstract: Aqueous solutions of peroxyacids are stabilized by a polymeric stabilizer selected from a phosphino polycarboxylic acid, a poly(acrylic acid)-acrylamidoalkylpropane sulfonic acid co-polymer, or a poly(acrylic acid)-acrylamidoalkylpropane sulfonic acid-sulfonated styrene terpolymer. The polymer-stabilized peroxyacid solutions have applications in aseptic sterilization and disinfecting of surfaces.

Abstract: Embodiments of the present invention are directed to a plurality of substantially spherical microspheres comprising at least one API substantially dispersed in at least one polymer and a lyoprotectant on an outside surface of the plurality of substantially spherical microspheres, wherein the plurality of substantially spherical microspheres have a D99[num] particle diameter of less than about 10 ?m; a D90[num] circularity value of from about 0.8 to about 1.0; and comprise API in a weight of about 20 to about 40 wt. % of the polymer. Other embodiments relate to injectable compositions comprising such microspheres and methods of treating a number of conditions by administering such injectable compositions to a subject.

Abstract: Compositions comprising select meroterpenes and a linoleic component and the use thereof in regulating the endocannabinoid system (ECS).

Abstract: The invention relates to citrate perhydrates and to the uses of citrate perhydrates, in particular as biocides, in particular pesticides, more particularly phytopharmaceuticals.

Abstract: The present invention relates generally to topical antiviral compositions, delivery systems, and methods of using the same.

Abstract: A composition and method for killing feral hogs: a bait that is attractive to hogs is mixed with a lethal amount of sodium nitrite, along with sufficient base to inhibit decomposition of the sodium nitrite. At sufficiently high pH, encapsulation of the sodium nitrite is not required to inhibit decomposition. In the absence of substantial decomposition, the sodium nitrite itself is not aversive to the pigs, and may even enhance acceptance of the baits by the pigs. Optionally, an anti-emetic compound is added to the mixture to reduce the likelihood the bait will be vomited. Optionally, an additional toxicant such as luteolin is added to the mixture.

Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.

Abstract: The present invention relates to the reduction of stress in ruminants in need thereof.

Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).

Abstract: Disclosed are compositions that include a combination of natural tooth powder ingredients pressed into tablet form, and methods of making the composition, and to methods of enhancing dental hygiene that includes administration of the composition. The compositions include natural ingredients such as xylitol and at least one tooth cleaning agent, and can be formed into a tablet suitable for cleaning the teeth without the use of a toothbrush or water.

Abstract: This disclosure relates to a composition for coloring hair containing comprising a multi-lamellar gel emulsion, which includes a haircolor formulation, and a method of making the same. The multi-lamellar gel emulsion includes about 0.5 wt % to about 4.0 wt % of cosmetically acceptable emulsifying fats, a cosmetically acceptable non-ionic surfactant, a water-soluble suspending polymer, and at least 80 wt % of water.

Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.

Abstract: In accordance with the present disclosure, there are provided formulations comprising: (a) at least one active agent; (b) an oil, and optionally a thickener therefor; (c) an organic solvent, and a thickener therefor; and (d) an oil and/or solvent soluble skin penetration enhancer; wherein: said formulation comprises <10 wt % water; and said formulation optionally forms a thixotropic thinning gel. Also provided are gels comprising oil and organic solvent, methods for preparing same and methods for the topical delivery of an active agent to a subject in need thereof.

Abstract: A composition and method for treating a subject following myocardial infarction are provided. The composition includes a non-PEGylated liposome. The method includes administering a non-PEGylated liposome to a subject in need thereof following myocardial infarction.